Evolving Takeda Signals Intent To Build Around Entyvio, GI Franchise
Executive Summary
Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.